{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.5"},{"groupId":"OG001","value":"62.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"262"},{"groupId":"OG001","value":"261"}],"units":"Participants"}],"description":"Minimal residual disease negative rate was defined as the percentage of participants with a best overall response of CR with MRD-negative disease status (that is, \\<5 mantle cell lymphoma \\[MCL\\] cell per 10,000 leukocytes for detection using the MRD assay), as assessed by flow cytometry of a bone marrow and/or peripheral blood sample.","groups":[{"description":"Participants received 4 capsules of ibrutinib-matching Placebo administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or study end, whichever occurred first. All participants also received a maximum of 6 cycles of BR background therapy (bendamustine hydrochloride 90 milligrams per meter square \\[mg/m\\^2\\] intravenous \\[IV\\] infusion on Days 1 and 2 of each cycle and rituximab 375 mg/m\\^2 IV infusion on Day 1 of each cycle), unless disease progression or unacceptable toxicity prior to Cycle 6. Participants with a complete response (CR) or partial response (PR) continued to receive background therapy with rituximab maintenance (375 mg/m\\^2 IV infusion) on Day 1 every second cycle starting at Cycle 8 for a maximum of 12 additional doses unless disease progression or unacceptable toxicity. Each cycle was of 28 days. Participants received treatment A up to 100.1 months. After treatment unblinding at the time of the primary analysis, participants randomized to Treatment A discontinued placebo treatment.","id":"OG000","title":"Placebo + Bendamustine and Rituximab (BR) (Treatment A)"},{"description":"Participants received ibrutinib capsules 560 mg (4\\*140 mg capsule) administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or study end, whichever occurred first. All participants also received a maximum of 6 cycles of BR background therapy (bendamustine hydrochloride 90 mg/m\\^2 IV infusion on Days 1 and 2 of each cycle and rituximab 375 mg/m\\^2 IV infusion on Day 1 of each cycle), unless disease progression or unacceptable toxicity prior to Cycle 6. Participants with a CR or PR continued to receive background therapy with rituximab maintenance (375 mg/m\\^2 IV infusion) on Day 1 every second cycle starting at Cycle 8 for a maximum of 12 additional doses unless disease progression or unacceptable toxicity. Each cycle was of 28 days. Participants received treatment B up to 117.2 months. After treatment unblinding at the time of the primary analysis, participants randomized to Treatment B continued treatment with ibrutinib at the discretion of the investigator.","id":"OG001","title":"Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B)"}],"paramType":"NUMBER","populationDescription":"ITT analysis set included all randomized participants and classified according to the assigned treatment group, regardless of the actual treatment received. CR participants with missing MRD data and participants who did not achieve a CR were considered nonresponders.","reportingStatus":"POSTED","timeFrame":"Up to 97 months","title":"Minimal Residual Disease (MRD)-Negative Response Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}